Change from baseline (difference vs placebo) over 6 weeks
| Aclidinium (N=171) | Tiotropium (N=158) | |
| E-RS | ||
| Total scorea | - 2.0*** | -1.2* |
| Breathlessness | - 1.1*** | - 0.7** |
| Cough and sputum | - 0.4** | - 0.2 |
| Chest symptoms | - 0.5** | - 0.3* |
| COPD additional symptoms | ||
| Night-time symptom severityb | - 0.14** | - 0.07 |
| Nocturnal awakenings (n) | - 0.12 | - 0.06 |
| Early-morning symptom severityb | - 0.22*** | - 0.12* |
| Coughc | - 0.17** | - 0.10 |
| Wheezec | - 0.14* | - 0.06 |
| Shortness of breathc | - 0.20** | - 0.11 |
| Phlegm clearancec | - 0.17* | - 0.07 |
| Activity limitation due to symptomsb | - 0.18** | - 0.08 |
| Relief medication-free days (%) | 9.6* | 8.9* |
LS mean differences: *p<0.05, **p<0.01, ***p<0.001 vs placebo (ANCOVA). Scales: a0-40; b1-5; c0-4 (reduction=improvement).